Latest News

Latest News

NICE publish final guidance for idelalisib to treat CLL, moving England and Wales NHS access closer

NICE published Final Guidance today on Idelalisib for treating chronic lymphocytic leukaemia

NICE technology appraisal guidance [TA359] http://www.nice.org.uk/guidance/TA359

 

This publishing of final guidance moves the treatment of idelalisib plus rituximab one step closer to NHS availability for England and Wales patients with NHS access expected within 3 months.

 

NICE approves idelalisib (Zydelig®) for the treatment of chronic lymphocytic leukaemia in England and Wales

 NICE says yes to new class of drug for adults with leukaemia

Today, the National Institute for Health and Care Excellence (NICE) has announced that idelalisib, in combination with rituximab, will be made available on the NHS in England and Wales for patients with chronic lymphocytic leukaemia (CLL). 

Update on the current Cancer Drugs Fund list - Two drugs for treating CLL planned to be withdrawn

On Friday 4th of September 2015 the England National Cancer Drug Fund announced results of the prioritisation review of drug listings. It is very disappointing to learn that two drugs for treating CLL patients are planned to be withdrawn by the 1st of November: bendamustine for treating relapsed CLL patients and ibrutinib for treating relapsed/refractory patients.

We are preparing to take action against this decision and are coordinating with leading clinicians and the wider CLL community to make a formal appeal to CDF  

NICE asks for further information to make a final decision on use of idelalisib with rituximab to treat adults with chronic lymphocytic leukaemia

18 June 2015

NICE has asked for further information from the company to make a final decision on the use of idelalisib in combination with the drug rituximab for adults with chronic lymphocytic leukaemia whose disease is refactory to other treatments when it is not considered appropriate to treat again with previous therapies.

NICE publishes guidance for NHS England & Wales use of obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA343] Published today June 2015

You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta343

Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:

NICE publishes guidance for NHS England & Wales use of ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA344] Published today June 2015
You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta344

Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended as a possible treatment for people with untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are not suitable.

What does this mean for me?

Idelalisib gains SMC approval for NHS Scotland use + early access programme

Idelalisib (Zydelig) has been accepted for restricted use by NHS Scotland. you can read more & access the full guidance PDF from the download on the SMC website.  

CLLSA have participated in the consultation process,  it is rewarding to see this now gain approval.  

SMC intitial guidance details:

following a full submission